1 / 26

Faculty Disclosure

Faculty Disclosure.

noble-sexton
Télécharger la présentation

Faculty Disclosure

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Faculty Disclosure In accordance with ACCME guidelines, any individual in a position to influence and/or control the content of this ASCP CME activity has disclosed all relevant financial relationships within the past 12 months with commercial interests that provide products and/or services related to the content of this CME activity. The individual below has responded that he/she has no relevant financial relationship(s) with commercial interest(s) to disclose: William K. Funkhouser, MD PhD

  2. Molecular Pathology: The Future Wm. K. Funkhouser, MD PhD UNC Pathology & Lab Medicine

  3. Our Future Pathology Practice will be: Citius - Faster Altius - Higher Fortius - Stronger

  4. Citius - Faster

  5. Faster Transfer from Discovery to Practice • Galen to Harvey: Millennium • Scurvy to citrus on ships: Century • PCN to production: Decades • HER2 amp, EGFR muts to Rx: Years • ASCO meets annually….

  6. Faster Technology Automation of chemistry Miniaturization of chemistry Computer analysis of data

  7. Faster Risk Estimates • For clinically unaffected individuals: • Etiologic mutation screening for couples • Etiologic mutation screening of relatives

  8. Faster Diagnosis Molecular subtypes Specific translocations Germline etiologic mutations

  9. Faster Prognosis • Hemochromatosis • A1AT deficiency • Cystic fibrosis • Medullary thyroid Ca in MEN2 • MMR-defective colorectal Ca

  10. Faster Prediction of Therapeutic Response Individual differences in drug metabolism “Druggable” mutant protein kinases ID of resistance mutations

  11. Faster Detection of Copy Number Variation Gene Amplification Allelic Loss Multiplex testing ISH

  12. Faster Translocation Detection Metaphase spreads Locus-specific probes

  13. Faster Sequence Variation Detection • Prenatal/Newborn screening • HLA loci • Germline vs. neoplasm muts • Fusion partners • Clonal Ig or TCR

  14. Faster Epigenetic Testing Histone protein modification DNA promoter methylation Imprinting abnormalities

  15. Faster RNA Abundance Cluster Analysis mRNAs µRNAs Their equilibria

  16. Altius - Higher

  17. Higher Complexity Multi-analyte tests Traits Statistics

  18. Higher Confidence Risk prediction Diagnostic, prognostic, predictive Management guidance

  19. Higher Productivity Timely reporting of accurate diagnoses with useful predictive data Prompt guidance of the treating clinician, particularly re. expensive targeted therapies

  20. Fortius - Stronger

  21. Stronger Associations Statistical associations Organizational associations

  22. Stronger Opinions Education of lawyers, legislators, judges, and payors

  23. Stronger Conclusions • Better diagnostic reproducibility • Better diagnostic accuracy • Better outcome prediction • Better management guidance

  24. .

  25. Going forward, Molecular Pathology will Improve our understanding of disease risk, etiology, pathogenesis, and outcomes Complement morphology Benefit our patients, our treating clinicians, and ourselves

  26. Thanks to: Drs. Myers, Humphrey, DeYoung (ADASP Leaders) Drs. Eberhard, Sepulveda, and Pfeifer (Speakers) Drs. Gulley, Weck, Tsongalis, and Nowak (AMP) You, for participating in this ADASP meeting

More Related